{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:15Z","timestamp":1793998035207,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Research Institute for Veterinary Science, Seoul National University.","award":["No grant ID"],"award-info":[{"award-number":["No grant ID"]}]},{"name":"The Research Institute for Veterinary Science, Seoul National University.","award":["No grant ID"],"award-info":[{"award-number":["No grant ID"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sodium-glucose cotransporter 2 inhibitors are widely used in human medicine for their insulin-independent glucose-lowering effects. However, their clinical efficacy and safety for managing diabetes mellitus in dogs have not been established. This study aimed to evaluate the efficacy and safety of DWP16001, a selective sodium-glucose cotransporter 2 inhibitor, as an adjunct to insulin therapy for client-owned dogs with diabetes mellitus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multicenter, randomized, double-blind, placebo-controlled clinical trial involved 61 dogs receiving stable insulin therapy. They were randomly assigned to receive DWP16001 (0.025\u00a0mg\/kg PO q24h) or placebo for 8 weeks. The changes in the serum fructosamine (weeks 0, 1, 4, and 8) and HbA1c (weeks 0, 4 and 8) concentrations and daily insulin dose were assessed. Safety evaluations included adverse event monitoring, physical examination, body weight measurement, blood gas and ketone analyses, urinalysis, and hematologic and biochemical profiling. Hypoglycemia was detected via blood glucose curve.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>DWP16001 significantly reduced fructosamine and HbA1c concentrations in the dogs, especially in those with poor baseline glycemic control (fructosamine\u2009\u2265\u2009500 \u00b5mol\/L, HbA1c\u2009\u2265\u20096%). A trend toward reduced insulin requirements was observed in the treatment group without significant weight loss or clinically relevant changes in systolic blood pressure or signs of volume depletion. Asymptomatic hypoglycemia was detected in four dogs receiving DWP16001, but it resolved following insulin dose adjustment. No episodes of diabetic ketoacidosis were recorded, and laboratory parameters remained stable throughout the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DWP16001 is a safe and effective adjunct to insulin therapy for diabetic dogs, especially those with suboptimal glycemic control. It demonstrated insulin-sparing effects and favorable metabolic safety, necessitating further evaluation in long-term clinical studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12917-025-04962-y","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:12:29Z","timestamp":1754971949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Ju-Hyun","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Gee","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Namkung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Gyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Woo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Bong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Young","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ok","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"issue":"11","key":"4962_CR1","doi-asserted-by":"publisher","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","volume":"309","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter Inhibition in the management of type 2 diabetes mellitus. Am J Physiol-Renal Physiol. 2015;309(11):F889-900.","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"1","key":"4962_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11\u201326.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4962_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330.","journal-title":"Drugs"},{"issue":"2","key":"4962_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1479164112441190","volume":"9","author":"C Foote","year":"2012","unstructured":"Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabet Vasc Dis Res. 2012;9(2):117\u201323.","journal-title":"Diabet Vasc Dis Res"},{"key":"4962_CR5","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098\u2013107.","journal-title":"Diabetologia"},{"issue":"8","key":"4962_CR6","doi-asserted-by":"publisher","first-page":"S2072","DOI":"10.1093\/jn\/134.8.2072S","volume":"134","author":"JS Rand","year":"2004","unstructured":"Rand JS, Fleeman LM, Farrow HA, Appleton DJ, Lederer R. Canine and feline diabetes mellitus: nature or nurture? J Nutr. 2004;134(8):S2072\u201380.","journal-title":"J Nutr"},{"issue":"4","key":"4962_CR7","first-page":"18","volume":"3","author":"K Qadri","year":"2015","unstructured":"Qadri K, Ganguly S, Praveen PK, Wakchaure R. Diabetes mellitus in dogs and its associated complications: a review. Int J Rec Biotech. 2015;3(4):18\u201322.","journal-title":"Int J Rec Biotech"},{"issue":"4","key":"4962_CR8","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/bcp.15613","volume":"89","author":"B Kim","year":"2023","unstructured":"Kim B, Huh KY, Hwang JG, Nah J, Huh W, Cho JM, Jang IJ, Yu KS, Kim Y, Lee S. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium\u2013glucose cotransporter 2 inhibitor and Metformin in healthy subjects. Br J Clin Pharmacol. 2023;89(4):1462\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4962_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bcp.15891","volume":"90","author":"SJ Lee","year":"2024","unstructured":"Lee SJ, Bae SH, Jeon S, Ji HY, Han S. Combined translational pharmacometrics approach to support the design and conduct of the first-in\u2010human study of DWP16001. Br J Clin Pharmacol. 2024;90(1):286\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4962_CR10","doi-asserted-by":"publisher","first-page":"e1454","DOI":"10.1002\/vms3.1454","volume":"10","author":"JH An","year":"2024","unstructured":"An JH, Choi HS, Choi JS, Lim HW, Huh W, Oh YI, Park JS, Han J, Lim S, Lim CY. Effect of the sodium-glucose cotransporter\u20102 inhibitor, DWP16001, as an add\u2010on therapy to insulin for diabetic dogs: a pilot study. Veterinary Med Sci. 2024;10(3):e1454.","journal-title":"Veterinary Med Sci"},{"issue":"3","key":"4962_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/jvim.17053","volume":"38","author":"JR Box","year":"2024","unstructured":"Box JR, Oyama MA, Mosenco AS, Hess RS. Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin\u2010treated diabetic dogs. J Vet Intern Med. 2024;38(3):1353\u20138.","journal-title":"J Vet Intern Med"},{"issue":"aop","key":"4962_CR12","first-page":"1","volume":"1","author":"EN Behrend","year":"2024","unstructured":"Behrend EN, Ward CR, Chukwu V, Cook AK, Kroh C, Lathan P, May J, Schermerhorn T, Scott-Moncrieff JC, Voth R. Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. J Am Vet Med Assoc. 2024;1(aop):1\u201311.","journal-title":"J Am Vet Med Assoc"},{"issue":"1","key":"4962_CR13","first-page":"52","volume":"86","author":"SL Benedict","year":"2022","unstructured":"Benedict SL, Mahony OM, McKee TS, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus. Can J Vet Res. 2022;86(1):52\u20138.","journal-title":"Can J Vet Res"},{"issue":"1","key":"4962_CR14","doi-asserted-by":"publisher","first-page":"44128","DOI":"10.1038\/srep44128","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen J, Fan F, Wang J, Long Y, Gao C, Stanton R, Xu Y. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7(1):44128.","journal-title":"Sci Rep"},{"issue":"6","key":"4962_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/vec.12513","volume":"26","author":"K Datte","year":"2016","unstructured":"Datte K, Guillaumin J, Barrett S, Monnig A, Cooper E. Retrospective evaluation of the use of glucagon infusion as adjunctive therapy for hypoglycemia in dogs: 9 cases (2005\u20132014). J Vet Emerg Crit Care. 2016;26(6):775\u201381.","journal-title":"J Vet Emerg Crit Care"},{"key":"4962_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S240903","author":"P Maffei","year":"2023","unstructured":"Maffei P, Bettini S, Busetto L, Dassie F. SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations. Diabet Metabol Syndr Obes. 2023. https:\/\/doi.org\/10.2147\/DMSO.S240903.","journal-title":"Diabet Metabol Syndr Obes"},{"issue":"3","key":"4962_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2460\/ajvr.81.3.233","volume":"81","author":"F Del Baldo","year":"2020","unstructured":"Del Baldo F, Magna L, Dondi F, Maramieri P, Catrina OM, Corradini S, Linari G, Golinelli S, Tardo AM, Bonfanti U. Comparison of serum fructosamine and glycated hemoglobin values for assessment of glycemic control in dogs with diabetes mellitus. Am J Vet Res. 2020;81(3):233\u201342.","journal-title":"Am J Vet Res"},{"issue":"3","key":"4962_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1040638719832071","volume":"31","author":"N-Y Kim","year":"2019","unstructured":"Kim N-Y, An J, Jeong J-K, Ji S, Hwang S-H, Lee H-S, Kim M-C, Kim H-W, Won S, Kim Y. Evaluation of a human glycated hemoglobin test in canine diabetes mellitus. J Vet Diagn Invest. 2019;31(3):408\u201314.","journal-title":"J Vet Diagn Invest"},{"issue":"3","key":"4962_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","volume":"11","author":"S Dutta","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022;11(3):927\u201340.","journal-title":"J Family Med Prim Care"},{"issue":"11","key":"4962_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(11):841\u201352.","journal-title":"Am J Hypertens"},{"issue":"24","key":"4962_CR21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"4962_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JF, McMurray JJ, Lindberg M, Rossing P. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"4962_CR23","doi-asserted-by":"publisher","first-page":"105910","DOI":"10.1016\/j.tvjl.2022.105910","volume":"289","author":"SJ Niessen","year":"2022","unstructured":"Niessen SJ, Bjornvad C, Church DB, Davison L, Esteban-Saltiveri D, Fleeman LM, Forcada Y, Fracassi F, Gilor C, Hanson J. Agreeing Language in veterinary endocrinology (ALIVE): diabetes mellitus-a modified Delphi-method-based system to create consensus disease definitions. Vet J. 2022;289:105910.","journal-title":"Vet J"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-025-04962-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-04962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:34:57Z","timestamp":1757414097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-025-04962-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4962"],"URL":"https:\/\/doi.org\/10.1186\/s12917-025-04962-y","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ARRIVE guidelines, institutional animal welfare regulations, and the principles of the Guide for the Care and Use of Laboratory Animals. The study protocol was approved by the Institutional Animal Care and Use Committee (DWP-IACUC-007), and written informed consent was obtained from all owners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}